• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Keys to personalized care in pancreatic oncology.

作者信息

Crane Christopher H, Iacobuzio-Donahue Christine A

出版信息

J Clin Oncol. 2012 Nov 20;30(33):4049-50. doi: 10.1200/JCO.2012.45.1799. Epub 2012 Oct 8.

DOI:10.1200/JCO.2012.45.1799
PMID:23045599
Abstract
摘要

相似文献

1
Keys to personalized care in pancreatic oncology.胰腺癌个性化治疗的关键。
J Clin Oncol. 2012 Nov 20;30(33):4049-50. doi: 10.1200/JCO.2012.45.1799. Epub 2012 Oct 8.
2
[Chemotherapy in adenocarcinomas of the pancreas].
Gastroenterol Clin Biol. 2002 Nov;26(11):1063; discussion 1063-4.
3
Preoperative chemoradiation therapy for adenocarcinoma of the pancreas: The Fox Chase Cancer Center experience, 1986-2003.胰腺腺癌的术前放化疗：福克斯蔡斯癌症中心的经验，1986 - 2003年
Surg Oncol Clin N Am. 2004 Oct;13(4):685-96, x. doi: 10.1016/j.soc.2004.06.013.
4
Adjuvant therapy following resection for pancreatic adenocarcinoma.胰腺腺癌切除术后的辅助治疗。
Surg Oncol Clin N Am. 2004 Oct;13(4):555-66, vii. doi: 10.1016/j.soc.2004.06.008.
5
[Combination therapy with lentinan, mitomycin c, 5-fluorouracil and radiation--a case of long-term survival of pancreas cancer after palliative surgery].香菇多糖、丝裂霉素C、5-氟尿嘧啶与放疗联合治疗——1例胰腺癌姑息性手术后长期生存病例
Gan To Kagaku Ryoho. 1987 May;14(5 Pt 1):1342-4.
6
[Histologic assessment of treatment effect of preoperative chemoradiation in patients presenting with resectable pancreatic adenocarcinoma].[可切除性胰腺腺癌患者术前放化疗治疗效果的组织学评估]
Cancer Radiother. 2011 Apr;15(2):97-105. doi: 10.1016/j.canrad.2010.06.019. Epub 2010 Nov 16.
7
The case for routine use of adjuvant therapy in pancreatic cancer.胰腺癌辅助治疗常规使用的理由。
J Surg Oncol. 2007 Jun 1;95(7):597-603. doi: 10.1002/jso.20719.
8
[Clinical study of the month. Adjuvant radio-chemotherapy and chemotherapy following curative resection of pancreatic cancer: results of the randomized trial ESPAC-1].[本月临床研究。胰腺癌根治性切除术后辅助放化疗与化疗：随机试验ESPAC-1的结果]
Rev Med Liege. 2002 Feb;57(2):119-22.
9
Radiation and chemotherapy. Treatment of localized pancreatic carcinoma.
J Fla Med Assoc. 1994 Jun;81(6):403-7.
10
Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma: The French SFRO-FFCD 97-04 Phase II trial.术前联合放疗及5-氟尿嘧啶和顺铂化疗在潜在可切除胰腺腺癌中的可行性：法国SFRO-FFCD 97-04 II期试验
Int J Radiat Oncol Biol Phys. 2006 Aug 1;65(5):1471-8. doi: 10.1016/j.ijrobp.2006.02.054. Epub 2006 Jun 21.

引用本文的文献

1
Feasibility of comprehensive genomic profiling using endoscopic ultrasound-guided tissue acquisition with a 22-gauge Franseen needle.使用22号 Franseen 针经内镜超声引导下组织采集进行综合基因组分析的可行性。
DEN Open. 2024 Apr 15;4(1):e365. doi: 10.1002/deo2.365. eCollection 2024 Apr.
2
Factors of Endoscopic Ultrasound-Guided Tissue Acquisition for Successful Next-Generation Sequencing in Pancreatic Ductal Adenocarcinoma.影响胰腺导管腺癌行超声内镜引导下组织获取用于下一代测序成功率的因素。
Gut Liver. 2020 May 15;14(3):387-394. doi: 10.5009/gnl19011.
3
Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine.
在个性化医学时代，用 PI3K 通路抑制剂对抗胰腺癌。
Gut. 2019 Apr;68(4):742-758. doi: 10.1136/gutjnl-2018-316822. Epub 2018 Nov 5.
4
UNR/CDSE1 expression as prognosis biomarker in resectable pancreatic ductal adenocarcinoma patients: A proof-of-concept.UNR/CDSE1表达作为可切除性胰腺导管腺癌患者预后生物标志物：一项概念验证研究。
PLoS One. 2017 Aug 1;12(8):e0182044. doi: 10.1371/journal.pone.0182044. eCollection 2017.
5
Pancreatic cancer biology and genetics from an evolutionary perspective.从进化角度看胰腺癌生物学与遗传学
Nat Rev Cancer. 2016 Sep;16(9):553-65. doi: 10.1038/nrc.2016.66. Epub 2016 Jul 22.
6
Identification of Poor-outcome Biliopancreatic Carcinoma Patients With Two-marker Signature Based on ATF6α and p-p38 "STARD Compliant".基于ATF6α和p-p38“符合STARD标准”的双标记特征识别预后不良的胆胰癌患者
Medicine (Baltimore). 2015 Nov;94(45):e1972. doi: 10.1097/MD.0000000000001972.
7
Reliable Detection of Somatic Mutations in Fine Needle Aspirates of Pancreatic Cancer With Next-generation Sequencing: Implications for Surgical Management.利用下一代测序技术可靠检测胰腺癌细针穿刺抽吸物中的体细胞突变：对外科治疗的意义
Ann Surg. 2016 Jan;263(1):153-61. doi: 10.1097/SLA.0000000000001156.
8
Nanoparticle formulation of ormeloxifene for pancreatic cancer.用于胰腺癌的奥莫昔芬纳米颗粒制剂
Biomaterials. 2015;53:731-43. doi: 10.1016/j.biomaterials.2015.02.082. Epub 2015 Mar 26.
9
Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer.吉西他滨在人胰腺癌中的递送及传质的瘤内异质性
Phys Biol. 2014 Nov 26;11(6):065002. doi: 10.1088/1478-3975/11/6/065002.
10
Functional p38 MAPK identified by biomarker profiling of pancreatic cancer restrains growth through JNK inhibition and correlates with improved survival.通过胰腺癌生物标志物分析鉴定出的功能性p38丝裂原活化蛋白激酶通过抑制JNK抑制生长，并与生存率提高相关。
Clin Cancer Res. 2014 Dec 1;20(23):6200-11. doi: 10.1158/1078-0432.CCR-13-2823. Epub 2014 Jun 24.